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Received 3 September 2009; received in revised form 3 March 2010; accepted 18 March 2010Abstract Induced pluripotent stem (iPS) cells are generated by nuclear reprogramming of mature cells to a pluripotent state,
and show biological properties of embryonic stem (ES) cells. The observation that human (h)ES cells generate hemoangiogenic
progeny, defined by their high-level expression of KDR and low-level expression of PDGFRα (KDR+PDGFRαlo) via WNT and BMP
signaling during 5-8 days of differentiation in a serum-free environment led us to address how hiPS cells give rise to
hemoangiogenic progeny. In the presence of WNT3a, four hiPS cell lines derived from human skin fibroblasts commonly
generated KDR+ and/or PDGFRα+ progeny by day 8 of differentiation. Endogenous BMP signaling was required for the
WNT3a-directed upregulation of hemogenic cell development and the hemoangiogenic activity was confined in all cases to the
KDR+PDGFRαlo fraction. Thus, iPS cells derived from human skin fibroblasts resemble hES cells in the generation of
hematopoietic and endothelial cells in vitro.
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Only a year after Dr. S. Yamanaka and his colleagues first
reported the induction of pluripotent embryonic stem (ES) cell-
like cells from mouse fibroblasts by application of their unique
gene-transfer-based nuclear reprogramming technology, and
provided the name ‘induced pluripotent stem’ (iPS) cell
(Takahashi and Yamanaka, 2006), human fibroblasts were
successfully reprogrammed to pluripotent stem cells (Yu et al.,
2007; Takahashi et al., 2007). Furthermore, by application of
removable, non-viral and/or non-integrative vectors for gene
transfer, or by replacement of (some)cDNAswithproteins and/
or small molecules, the technology that depended initially on
stable integration of four cDNAs has been developed to the
stage where the iPS cells contain no transgenes (Okita et al.,.
224 Y. Wang et al.2008; Huangfu et al., 2008; Yu et al., 2009; Yusa et al., 2009;
Zhou et al., 2009; Woltjen et al., 2009; Kim et al., 2009). Such
technical improvements have opened a path toward clinically
relevant, patient-specific pluripotent stem cells for personal-
ized regenerative medicine based on iPS cells (Dimos et al.,
2008; Ebert et al., 2009; Soldner et al., 2009). However, the
resemblance of iPS cells to ES cells suggests that simple
transplantation of iPS cells into an adult body will likely
result in teratoma consisting of divergent cell-types, many
of which are unwanted. As for ES cells, directed differen-
tiation of iPS cells to the precursor cell of interest will be
required before transplantation. The use of transgene
expression to control differentiation is unsuitable for
developing clinically relevant cell populations. It is there-
fore crucial to establish the signalling principles that govern
pluripotent stem cell differentiation toward specific cell
lineage so that proteins and small molecules can be used to
direct the differentiation.
Like ES cells, iPS cells are capable of self-renewal and
differentiation towards mature cells originating from all
three germ layers, including cardiac, neural, and erythro-
myeloid cells (Hanna et al., 2007; Mauritz et al., 2008;
Narazaki et al., 2008; Choi et al., 2009; Hirami et al., 2009;
Karumbayaram et al., 2009; Niwa et al., 2009; Senju et al.,
2009; Zhang et al., 2009). We have previously demonstrated
the essential role of the WNT-BMP signalling network in
directing hES cell differentiation toward precursor of
hematoendothelial lineages under serum-free conditions
(Wang and Nakayama, 2009). The KDR+PDGFRαlo precursors
develop from days 3-5 of differentiation and represent the
entire hemoangiogenic activity generated at this stage.
However, it has not been demonstrated whether hiPS cells
respond to WNTs and BMPs like hES cells during differenti-
ation. This question is addressed here with hiPS cell lines
established from fibroblasts at different stages of ontogeny:
iPS(IMR90)2 from the fetal fibroblast cell line IMR90, and iPS
(foreskin)1, 2 and 4 from primary neonatal foreskin
fibroblasts (Yu et al., 2007). WNT signalling increased
hematopoietic differentiation of all iPS cells tested,
although the overall efficiency and exogenous factor-
dependency differed among clones. Furthermore, the
hemogenic activity was invariably enriched in the
KDR+PDGFRαlo progeny population. WNT effects depended
on the activation of endogenous BMP signaling during
differentiation.
Results
Exogenous WNT3a but not BMP4 promotes the
development of hemogenic cells from hiPS cells
Based on the results with hES cells (Wang and Nakayama,
2009), we hypothesized that WNT signaling would direct hiPS
cells to differentiate to hematoendothelial cells. Human iPS
cells were differentiated to form an embryoid body (EB) with
and without BMP4 or WNT3a, and the resulting EB cells were
subjected to the OP9 co-culture (Fig. 1A). As for EBs derived
from HES3 cells (Fig. 1C), those derived from iPS(foreskin)1
cells in the presence of WNT3a gave rise to CD45+CD33+
myeloid-like non-adherent cells on OP9 in two weeks
(Fig. 1B). However, the EBs from hiPS cells differed in thata low level of CD45+CD33+ cells accumulated even when the
EBs were formed in the absence of exogenous factor
(Fig. 1B).
The quantitative effect of exogenous factor on hemato-
poietic differentiation of hiPS cells was determined by a
hemogenesis assay: a brief co-culture on OP9 followed by
counting of erythro-myeloid (EM) colony-forming cells (CFCs)
(Wang and Nakayama, 2009) (Fig. 1D). The hiPS-derived EBs
formed in the presence of WNT3a (W) generated 148±28.6
EM-CFCs/105 EB cells. When BMP4 (B) was present during
differentiation (Fig. 1D, middle panel), only 16.7±1.76 EM-
CFCs/105 EB cells were produced. Similarly, the hES-derived
EB cells gave rise to 117±10.3 (W) and 11.7±5.93 (B) EM-
CFCs/105 EB cells, respectively (Fig. 1D, bottom panel). In
contrast, consistent with the long-term OP9 co-culture
experiments (Figs. 1B, C), the iPS-derived EBs formed in
the absence of factor (None) generated more EM-CFCs (21.0
±4.58/105 EB cells) than the hES-derived EBs (6.33±4.48/
105 EB cells). Nevertheless, exogenous WNT3a, but not
BMP4, upregulated the level of hemogenic activity during
iPS(foreskin)1 cell differentiation. IPS(foreskin)4 cells pro-
duced a similar level of hemogenic cells when differentiated
in the presence of WNT3a, although spontaneous generation
was more pronounced (Supplemental Figure [S. Fig.] 1).
These results indicate that fibroblast-derived hiPS cells
resemble hES cells in their efficient generation of hemogenic
cells in response to exogenous WNT3a.WNT3a stimulates the generation of
KDR+PDGFRαlo EB cells from hiPS cells
The hemoangiogenic activity developed from hES cells is
confined to the KDR+PDGFRαlo EB cell fraction (Wang and
Nakayama, 2009). Therefore, we determined whether WNT
signaling stimulates the generation of KDR+PDGFRαlo progeny
from hiPS cells.
As for HES3 cells, the undifferentiated hiPS cells expressed
KDR very weakly, and a minor fraction of them expressed
PDGFRα (Figs. 2A and B, and S.Fig. 2, ‘Day 0’). Upon
differentiation, KDR-PDGFRα+ (black) and KDR+PDGFRα+
(red) cells were upregulated/generated in the absence of
exogenous protein factors (‘None’). However, the emergence
of the KDR+PDGFRαlo progeny (K+Plo, green) was minimal.
When WNT3a was added from day 0 of differentiation, the
KDR+PDGFRαlo fraction was preferentially upregulated from
all hiPS and hES cell lines tested, albeit at varying levels (‘W’).
In this sense, the response of hiPS cells to exogenous WNT3a
during differentiation was similar to that of hES cells.
However, consistent with the results from hemogenic cell
analysis (S.Fig. 1), iPS(foreskin)4 cells gave rise to a
significantly higher level of the KDR+PDGFRαlo progeny
spontaneously (S.Fig. 2 ‘None’).
In the case of hES cells, the developmental stage for the
hemogenic mesoderm/endothelium is between days 3 and 5
of differentiation. However CD45+ hematopoietic progenitor
cells are not detected, even on day 8 when CD34+CD31+ cells
are evident (Wang and Nakayama, 2009). Similarly, by day 8
of differentiation of iPS(foreskin)1 cells in the presence
of WNT3a, CD34+CD31+ EB cells were apparent (Fig. 2C, left
panel), but CD45+ cells were never observed (right panel).
Figure 1 WNT3a promotes hematopoietic cell development from hiPS cells. (A) Scheme for detection of hemogenic activity using total EB cells. IPS(foreskin)1 cells and HES3 cells were
differentiated in the presence of no factor (None), BMP4 (B), Noggin (N), WNT3a (W), or WNT3a+Noggin (WN) for 8 days. The resultant EB cells were sorted for PI-excluded cells (Live
cells), which were then individually cultured on OP9 cells. (B, C) Hematopoietic cell development from the hiPS-derived EB cells (B) and HES3-derived EB cells (C) on OP9. Non-adherent
hematopoietic cells that preferentially emerged fromWNT3a-treated EB cells in 14 days (right photos) were collected and analyzed by flow cytometry for CD33 and CD45 (left panels). (D)
Emergence of hemogenic activity. The OP9 co-culture was initiated with 2×105 EB cells, and all cells from each co-culture were subjected to the EM-CFC analysis on day 4. All erythro-
myeloid colonies (arrow heads top photo) were scored. The numbers of EM-CFCs were averaged (independent experiment number [n]=3) and plotted with error bars indicating±SEM, *
Pb0.05, ** Pb0.005. Corresponding data obtained from iPS(foreskin)4 cells are shown in S.Fig. 1. (E) Induction of hemoangiogenic mesoderm gene expression. RNAs isolated from day 6
iPS(foreskin)1 EBs were directly subjected to real-time RT-PCR analysis using the designated primers. The relative expression levels were averaged (n=4) and plotted with error bars









Figure 2 WNT3a promotes generation of the KDR+PDGFRαlo progeny from hiPS cells. (A, B) Flow cytometric analysis of Day 8 EBs. Left panels; iPS(foreskin)1 cells, iPS(IMR90)2 cells
and HES3 cells were directly subjected to FACS analysis (Day 0), or were differentiated for 8 days in the absence (None) or presence (W) of WNT3a. EB cells from the latter were then
subjected to FACS analysis. The KDR-PDGFRα+, KDR+PDGFRα+ and KDR+PDGFRαlo cell populations are represented as black, red and green dots, respectively. The percentage of total EB
cells in each fraction is shown in the same respective color. Right panels; the percentage of KDR+PDGFRαlo (K+Plo) cells generated on day 0 (Day 0), and on day 8 of differentiation with no
factor (None) or with WNT3a (W) is representative of 2–4 independent experiments. Corresponding data obtained from iPS(foreskin)4 cells are shown in S.Fig. 2. (C) Generation of
CD34+CD31+CD45- EB cells from hiPS cells. iPS(foreskin)1 cells differentiated in the presence of WNT3a for 8 days were subjected to FACS analysis for CD31, CD34 and/or CD45 expressing
cells. (D) Effect of Noggin on the KDR+PDGFRαlo cell generation from hiPS cells. The iPS(foreskin)1 and HES3 cells differentiated in the presence of no factor (None), Noggin (N), WNT3a
(W) and WNT3a+Noggin (WN) for 8 days were subjected to FACS analysis for KDR and/or PDGFRα expressing cells. The percentage of K+Plo cells in total EB cells was normalized against







227Regulation of hemogenesis from hiPS cellsThe WNT3a effects on differentiating hiPS cells
depend on endogenous BMP signaling
BMP signaling mediates the stimulation by WNT of
KDR+PDGFRαlo hemoangiogenic cell development from
hES cells (Wang and Nakayama, 2009). Therefore, we
addressed whether the WNT3a effects on hiPS cells also
depended on endogenous BMP signaling. When the BMP
inhibitor Noggin was added with WNT3a during iPS(foreskin)
1 and iPS(foreskin)4 cell differentiation, the hemogenic
activity induced by WNT3a alone was virtually abolished
(Fig. 1D and S.Fig. 1, ‘WN’) and the WNT-upregulated
portion of the KDR+PDGFRαlo cell population was reduced
to the basal level by Noggin (Fig. 2D and S.Fig. 2, ‘WN’).
Furthermore, Noggin completely inhibited the induction by
WNT3a of the hemoangiogenic cell marker transcripts,
CDH5 and TAL1 (Fig. 1E, ‘WN’). These data indicate that
the effects of WNT3a on differentiating hiPS cells require
the involvement of BMP signaling, probably activated by
endogenous BMPs.Figure 3 Gene expression profile of the KDR+PDGFRαlo progeny der
iPS(foreskin)2 cells ( ) were differentiated for 8 days in the presenc
were individually collected from the resulting EBs by FACS. RNAs fr
designated primers. The data are representative of 3–4 independen
presented in S.Fig. 3A, B. Corresponding data from iPS(foreskin)4 ceGene expression profile of the hiPS cell-derived
KDR+PDGFRαlo progeny
The lineage of cells included in the KDR+PDGFRαlo fraction
developed in the presence of WNT3a from hiPS cells was
determined by fluorescence-activated cell sorting (FACS)
and reverse transcription-polymerase chain reaction (RT-
PCR). We compared the levels of lineage-specific transcripts
in each of the four sorted fraction: KDR-PDGFRα- (double
negative, or ‘DN’), KDR-PDGFRα+ (K-P+), KDR+PDGFRα+
(double positive or ‘DP’) and KDR+PDGFRαlo (K+Plo), derived
from differentiated HES3 cells (Fig. 3 and S.Fig. 3, white
bar), iPS(foreskin)1 cells (black bar), and iPS(foreskin)2 cells
(dark gray bar). The POU5F1 (OCT4) transcript, a marker for
undifferentiated pluripotent stem cells, was detected at
high levels in undifferentiated hES (‘ES’) and hiPS (‘iPS’)
cells, and very low levels in all other sorted fractions
(S. Fig. 3). The early mesoderm transcripts T and MESP1,
and the lateral plate/extraembryonic mesoderm transcript
FOXF1 were found in all KDR+ and/or PDGFRα+ cells withived from hiPS cells. HES3 cells (□), iPS(foreskin)1 cells (■), and
e of WNT3a and the indicated four fractions (DN, K-P+, DP, K+Plo)
om each fraction were subjected to real-time RT-PCR using the
t experiments, shown with error bars (±SD). Additional data are
lls are shown in S.Fig. 3C.
228 Y. Wang et al.significantly higher expression in the DP cell fraction (Fig. 3).
These results suggest that WNT3a induces differentiation of
hiPS cells towards mesodermal lineages. In addition, the
expression of hemoangiogenic cell marker genes such as
TAL1, CDH5, RUNX1 andGATA2 (Fig. 3), andMYB and CD34 (S.
Fig. 3) was detected almost exclusively in the KDR+PDGFRαlo
fraction, suggesting that this fraction is enriched in the
hemogenic activity. Essentially the same results were
obtained from iPS(foreskin)4 cells (S.Fig. 3C). Thus, the
gene expression profile of the iPS-derived KDR+ and/or
PDGFRα+ progeny is almost identical to that of the hES-
derived progeny when generated in the presence of WNT3a.
The hemoangiogenic potential of the
WNT3a-induced KDR+PDGFRαlo progeny
from hiPS cells
Transcript analyses predicted that WNT3a-induced
KDR+PDGFRαlo progeny from hiPS cells could generate
hematopoietic progenitor cells (Fig. 3). The FACS-purified
EB fractions derived from iPS(foreskin)1, 2 and 4 cells were
therefore individually subjected to EM-CFC and hemogenesis
assays (Wang and Nakayama, 2009). Only a few erythro-
myeloid colonies arose from any of the fractions tested
(Fig. 4A right panels and S.Fig. 4, white bar). In contrast, the
KDR+PDGFRαlo cell fraction showed the exclusive ability to
give rise to many erythro-myeloid colonies after the 4-dayFigure 4 The WNT3a-induced KDR+PDGFRαlo cells from hiPS cells
activity from hiPS cells. IPS(foreskin)1 and iPS(foreskin)2 cells were
(DN, K-P+, DP, K+Plo) were collected as described for Fig. 3. 2.5×104 c
EM-CFC assay (□, right panels), or plated onto OP9 cells and co-cultu
to EM-CFC analysis (■). (B) CFU-End from hiPS cells. The KDR+PDGF
cells and iPS(foreskin)2 cells were individually cultured on OP9 for 1
antibody (upper photos), and the stained colonies were counted (bo
averaged (n=3 for iPS(foreskin)1, and n=2 for iPS(foreskin)2), and p
for iPS(foreskin)2, * Pb0.05. Corresponding data obtained from iPS(
(CDH5) is shown in S. Fig. 4.culture on OP9 (black bar). Thus, while the absolute numbers
of the EM-CFC derived from the WNT3a-induced
KDR+PDGFRαlo progeny varied among different hiPS cell
lines, the unique potency of the KDR+PDGFRαlo progeny to
generate hematopoietic progenitors was preserved.
Finally, we asked whether the hiPS cell-derived
KDR+PDGFRαlo progeny were able to generate endothelial
cells in culture. The KDR+PDGFRαlo cells generated from iPS
(foreskin)1, 2 and 4 cells in the presence of WNT3a were
individually cultured on OP9 cells and endothelial cell colonies
were visualized via the marker CD31 and CDH5 (Fig. 4B and S.
Fig. 4). The number of positive colony was scored to quantify
the endothelial cell precursors (colony forming unit-endothe-
lial cell, or CFU-End). The data clearly showed that the WNT-
induced-KDR+PDGFRαlo progeny from all hiPS cell lines
generated endothelial cell precursors, despite variation in
the absolute numbers of CFU-End among hiPS cell lines.
Discussion
We have shown that hiPS cells established from human skin
fibroblasts by stable integration of four reprogramming
genes: OCT4, NANOG, SOX2 and LIN28 (Yu et al., 2007)
resemble hES cells in differentiating toward precursor cells
of the hematoendothelial lineage. Blood cell formation from
miPS and hiPS cells has been reported (Hanna et al., 2007;
Choi et al., 2009; Niwa et al., 2009). However, we havehave both hemogenic and angiogenic potentials. (A) Hemogenic
differentiated in the presence of WNT3a and the four fractions
ells of each sorted fraction were either directly subjected to the
red for 4 days (left photos). The latter cells were then subjected
Rαlo cells derived in the presence of WNT3a from iPS(foreskin)1
0 days. The cultures were fixed and stained with the anti-CD31
ttom panel). The number of EM-CFCs (A) and CFU-Ends (B) were
lotted with error bars indicating ±SEM for iPS(foreskin)1 and ±SD
foreskin)4 cells are shown in S.Fig. 4. Expression of VE-cadherin
229Regulation of hemogenesis from hiPS cellsdemonstrated for the first time that the signaling requirement
for hiPS cells to generate hemoangiogenic progeny is similar to
that for hES cells; WNT signaling promoted the process in
cooperation with endogenously activated BMP signaling
(Figs. 1 and 2) (Wang and Nakayama, 2009).
The dependency of hiPS cells on exogenous WNT3a was,
however, less stringent than that for hES cells, as seen by the
more pronounced spontaneous generation of the
KDR+PDGFRαlo progeny during differentiation in the absence
of exogenous protein factor (Figs. 1 and 2) with hiPS cells
than the hES cells tested. In agreement with Choi, et al
(2009), we found that production of hemogenic cells in
response to exogenous factors such as WNT3a also differed
significantly among the hiPS cell lines tested, even though
they were derived from essentially the same fibroblast cell
type and maintained and differentiated by the same
methods. We suggest that among the major causes of the
spontaneous differentiation and clonal variation is the
difference in the level of WNTs and/or BMPs produced
endogenously during differentiation, as is the case for hES
cells where the spontaneous differentiation as evident by the
PDGFRα+ cell genesis is markedly reduced by Noggin or DKK1
(Wang and Nakayama, 2009). However, the capacity for
factor-independent differentiation may also contribute to
these differences, and may already have been determined at
the stage of maintenance culture. In fact, the effect of
Noggin on spontaneous genesis of the PDGFRα+ progeny from
hiPS cells was not marked (data not shown).
The differences between iPS cells and ES cells are
attributable, at least in part, to reactivation of transgene
expression during differentiation in the former. It remains to
be determined whether differences in the integration sites,
copy numbers, and expression levels of the transgenes
contribute to clonal variation and influence both factor-
dependent and factor-independent differentiation. Different
extents of reprogramming (Mikkelsen et al., 2008), differences
in the genetic and epigenetic background of cells to be
reprogrammed, and/or random mutations potentially intro-
duced during establishment of iPS cells would also cause such
variations, some of which are also attributed to the clonal
difference found among hES cell lines (Osafune et al., 2008). In
this context, it will be interesting to examine whether iPS cell
lines arising from a transgene-free reprogramming method
show more uniform in vitro differentiation, and whether the
lineage of cells used for reprogramming corresponds to a
specific differentiation property of the resulting iPS cells.
Nevertheless, the signalling principle established with hES
cells for the efficient genesis of hemoangiogenic cells seems to
be applicable to hiPS cells, confirming that hES cells are a
useful model not only for the study of early developmental
events occurring during human embryogenesis, but also as the
“gold standard” pluripotent stem cells to establish a universal
differentiation protocol applicable to a variety of iPS cells.
Materials and methods
Pluripotent cells, maintenance culture, and
differentiation culture
HES3 hES cells were grown in bulk culture on irradiated
primary mice embryonic fibroblasts (MEFs) in SR mediumsupplemented with 4 ng/ml human fibroblast growth factor 2
(FGF2, R&D Systems. Minneapolis, MN) (Wang and Nakayama,
2009). The human fibroblast-derived iPS cell lines: iPS
(foreskin)1, 2 and 4, and iPS(IMR90)2, were kindly provided
by J. Thomson (Madison, WI), and maintained on MEFs in SR
medium supplemented with 100 ng/ml FGF2 (Yu et al.,
2007). Differentiation of hES and hiPS cells was induced
in the Knockout Serum Replacement (KSR)-based serum-
free differentiation medium containing 0.9% (w/v) methyl-
cellulose (Stem Cell Technologies, Vancouver, BC, Canada)
with various factors, and incubated at 37 °C under 5%
CO2, 5% O2 (Wang and Nakayama, 2009). Human BMP4 and
human/mouse Noggin-Fc (R&D), and mouse WNT3a (Austra-
lian Stem Cell Centre) were added at 10, 500 and 100 ng/ml,
respectively.Flow cytometry
EBs were harvested and dissociated into single cells that
were stained with mouse anti-human PDGFRα (BD Bio-
sciences, North Ryde, NSW Australia) and anti-human
FLK1/KDR (RELIATech, Braunschweig, Germany) monoclonal
antibodies, and analyzed or sorted for PDGFRα and KDR
markers (Wang and Nakayama, 2009). Live cells were pre-
gated with propidium iodide (PI, Sigma-Aldrich, St Louis,
MO). For total EB cell assays, live EB cells were collected by
FACS as PI-excluding cells.Hemoangiogenesis assay using OP9 stromal cells
The FACS-fractionated EB cells (2.5×104) or FACS-purified
total EB cells (1-2×105) were plated onto 80-90% confluent OP9
cells and the co-culture was performed in the presence of
human stem cell factor (hSCF, Amgen, Thousand Oaks, CA),
human thrombopoietin (hTPO, Millipore, Temecula CA),human
interleukin-3 (hIL3, Millipore), and human granulocyte-macro-
phage colony-stimulating factor (hGM-CSF, Millipore) (Wang
and Nakayama, 2009). For the hemogenesis assay, the
whole co-cultures were harvested by a brief TrypLE-Select
(Invitrogen,MountWaverley VIC Australia) treatment on day 4,
followed by EM-CFC analysis.Erythro-myeloid colony-forming cell
(EM-CFC) analysis
Freshly isolated or OP9-co-cultured EB cells were added to
serum-free CFC medium (Nakayama et al., 2003), supple-
mented with hIL3, hSCF, human granulocyte colony stimu-
lating factor (hG-CSF, Millipore), hGM-CSF, hIL6 and human
erythropoietin (hEPO, Millipore), then divided into 2–4 35-
mm bacterial-grade dishes, and maintained at 37 °C under
5%CO2, 5%O2 (Wang and Nakayama, 2009). On day 11, total
colonies including colony-forming unit erythroid (CFU-E),
burst-forming unit erythrocyte (BFU-E), colony-forming unit
macrophage/monocyte (CFU-M), colony-forming unit granu-
locyte (CFU-G), and erythroid-monocyte/macrophage mixed
colony-forming unit (CFU-EM) were counted. Images of
colonies were acquired as described (Wang and Nakayama,
2009).
230 Y. Wang et al.Endothelial colony-forming cell analysis
1.25 x 104 FACS-fractionated EB cells were seeded onto OP9
cells, and cultured for 7–10 days in the presence of hSCF,
hIL3, hTPO and hGM-CSF. The cultures were fixed with
ethanol for indirect immunofluorescence staining with the
mouse anti-human CD31 and CDH5 antibodies (DAKO,
Glostrup, Denmark), and fluorescent colonies were scored
as described (Wang and Nakayama, 2009).
Real-time RT-PCR analysis
Total RNA was prepared, DNase I-treated, and reverse
transcribed into cDNA. Real-time quantitative PCR was
performed using the ABI 7500 (Applied Biosystems, Scoresby,
VIC Australia). The eukaryotic translation elongation factor 1
alpha 1 (EEF1A1) gene was used as a reference housekeeping
gene, and the relative expression values were calculated as
described (Wang and Nakayama, 2009).
Statistical analysis
Differences between groups were compared using the
Student t test (KaleidaGraph, Synergy Software, Reading,
PA). Results were considered not significant (ns) at P values
of 0.05 or greater.
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